Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biocon
Pharma
Settlement allows Sandoz to launch Eylea biosimilar in late 2026
Regeneron and Sandoz have resolved patent litigation related to a biosimilar version of Eylea, allowing it to launch in the fourth quarter of 2026.
Kevin Dunleavy
Sep 9, 2025 10:30am
Trump's tariffs, Leqembi, Kyowa Kirin—Fierce Pharma Asia
Apr 18, 2025 9:25am
AstraZeneca, GSK, Takeda—Fierce Pharma Asia
Nov 1, 2024 8:20am
Regeneron loses bid to block Amgen's Eylea biosim, sinking shares
Sep 24, 2024 10:32am
Granules receives Form 483 over poor document controls and more
Sep 19, 2024 10:11am
MediLink, Takeda, Ascentage and China NMPA—Fierce Pharma Asia
Jun 21, 2024 8:23am
